PROM1 and metastatic melanoma: In 2008, Rappa et al. investigated the effects of CD133 down-regulation in human metastatic melanoma, which result in slower cell growth, reduced cell motility, decreased capacity to form spheres under stem cell-like growth conditions and reduced capacity of the cells to metastasize.